Navigation Links
Popular diabetes treatment could trigger pancreatitis, pancreatic cancer
Date:4/30/2009

A drug widely used to treat Type 2 diabetes may have unintended effects on the pancreas that could lead to a form of low-grade pancreatitis in some patients and a greater risk of pancreatic cancer in long-term users, UCLA researchers have found.

In a study published in the online edition of the journal Diabetes, researchers from the Larry L. Hillblom Islet Research Center at UCLA found that sitagliptin, sold in pill form as Januvia, caused abnormalities in the pancreas that are recognized as risk factors for pancreatitis and, with time, pancreatic cancer in humans. Januvia is marketed by Merck & Co. Inc. Sitagliptin is a member of a new class of drugs that enhance the actions of the gut hormone known as glucagon-like peptide 1 (GLP-1), which has been shown to be effective in lowering blood sugar in people with Type 2 diabetes. The study is available at http://diabetes.diabetesjournals.org/cgi/content/abstract/db09-0058v1.

"Type 2 diabetes is a lifelong disease people often take the same drugs for many years, so any adverse effect that could over time increase the risk for pancreatic cancer would be a concern," said Dr. Peter Butler, director of the Hillblom Center and the study's lead investigator. "A concern here is that the unwanted effects of this drug on the pancreas would likely not be detected in humans unless the pancreas was removed and examined."

An observed connection between Byetta, a drug used to treat Type 2 diabetes that is related to Januvia in its intended actions, and pancreatitis has already been reported, prompting a Food and Drug Administration warning. Amylin Corp., which markets Byetta, has suggested that since there is no known mechanism linking the cases of pancreatitis with Byetta, the association might be chance. The UCLA study suggests that there may indeed be a link between drugs that enhance the actions of GLP-1 and pancreatitis by increasing the rate of formation of cells that line the pancreatic ducts.

In the study, researchers used human IAPP transgenic (HIP) rats to test both sitagliptin and metformin; metformin, a member of an older, different class of diabetes drugs in use since the 1950s, has recently been found to have anti-tumor properties. The researchers sought to determine how the drugs, both singly and in combination, affected islet disease progression in the pancreas particularly how they affected beta cells in the pancreas's Islets of Langerhans. Beta cells are responsible for releasing insulin in people with normal metabolism, but they don't produce insulin in sufficient amounts in diabetes patients. HIP rats approximate both the islets and metabolism of people with Type 2 diabetes. The drugs were tested in 40 rats for 12 weeks.

The researchers found that the two drugs in combination had a synergistic effect that helped preserve beta cells, improved their function and enhanced insulin sensitivity in the test rats. With the sitagliptin alone, however, the rats had abnormally high rates of cell production in their pancreatic ducts; a few developed an abnormality known as ductal metaplasia, and one developed pancreatitis.

But the metformin, trade name Glucophage, seems to counteract sitagliptin's adverse effect.

"The apparent protection against the unwanted actions of sitagliptin in the exocrine pancreas are intriguing and may offer a potential way of using the GLP-1 class of drugs safely," Butler said. "The protective effect may have been either by the actions of metformin to decrease blood glucose values or its recently appreciated properties as a tumor suppressive agent."

Butler noted that the present study was undertaken in rats and that it is possible the adverse effects observed would not occur in humans.

"Given these findings, it is probably sensible to use the GLP-1 class of drugs only with metformin until other data is forthcoming," he said.


'/>"/>

Contact: Enrique Rivero
erivero@mednet.ucla.edu
310-794-2273
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Renowned Smoking Cessation Expert Launches Popular Stop Smoking Seminar in UK
2. Breast Augmentation: Survey Highlights Recent Trends In Today's Most Popular Cosmetic Surgery Procedure
3. Popular gaming system may offer radiologists an alternative way to view patient images
4. Energy-Saving LED Replacement for Popular Appliance and Display-Case Light Fixture Design Now Available
5. Harris Corporation Redesigning Popular Radiology Web Site to Enhance Content Management and Accessibility
6. Research Finds Popular Household Pets Transmit Dangerous Parasites to Humans
7. LENA Foundation Revives Popular Online Child Language Assessment Tool
8. Liposuction No Longer the Most Popular Surgical Procedure According to New Statistics
9. Sexual lyrics in popular songs linked to early sexual experiences
10. Back by Popular Demand! DIAKADI Body Announces Its Spring Edition of Outdoor Boot Camps
11. Popular or Not? Your Genes May Help Decide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be ... a preset onto their media," said Christina Austin - CEO of Pixel Film Studios. ... quickly and easily add stylish color grades to their footage. A LUT is a ...
(Date:5/27/2016)... CA (PRWEB) , ... May 27, 2016 , ... More ... Health, so it is not surprising that bariatric surgery has received increased attention in ... Journal explains. Of course, when it comes to weight loss, most people are familiar ...
(Date:5/27/2016)... ... ... An influential resource amongst nurses and professionals in the health care world, ... of topics detailing why we appreciate nurses in so many different ways. From exclusive ... being in a major recession to one of the hottest growing professions in any ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response to meager ... are unaware of the plight of aphasia. In collaboration with the American Aphasia ... campaign. , The link between stroke and aphasia is relatively unknown, but through ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year Standard Process ... Outerbridge is this year’s Life University winner of a $2,500 scholarship ... Student Leadership Awards ceremony. , Outerbridge is approaching her last quarter at Life ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 Digital ... issuance to it by the US Patent and ... company,s technology includes proprietary processes for electronic opt-­in ... health and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows ...
(Date:5/24/2016)... Niederländische Chirurgen haben eine ... Ärzten erlaubt, ihre Expertise weltweit zu teilen und ... Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, in ... Europa, Afrika, Asien und den USA ... registriert. Information und Weiterbildung   ...
(Date:5/24/2016)... May 24, 2016  Diana Russell suffers from a ... from the inside out.  This disease has put her ... her children and grandchildren to leave her home.  Because ... family cannot haul the wheelchair.  So if there is ... and Diana is left to wait for the bus. ...
Breaking Medicine Technology: